Cargando…
Iodide Analogs of Arsenoplatins—Potential Drug Candidates for Triple Negative Breast Cancers
Patients with triple negative breast cancers (TNBCs)—highly aggressive tumors that do not express estrogen, progesterone, and human epidermal growth factor 2 receptors—have limited treatment options. Fewer than 30% of women with metastatic TNBC survive five years after their diagnosis, with a mortal...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434261/ https://www.ncbi.nlm.nih.gov/pubmed/34500854 http://dx.doi.org/10.3390/molecules26175421 |